How Wegovy Works in Your Body: the Evidence Behind the Weight Loss

The GLP-1 signal your body already produces — and what semaglutide adds to it

After you eat, cells lining your small intestine release a hormone called glucagon-like peptide-1, or GLP-1. It travels to the pancreas, the stomach and the brain, doing several things at once: prompting insulin release, slowing gastric emptying, and telling the hypothalamus to reduce hunger. The effect is real but brief, natural GLP-1 breaks down within minutes.

Semaglutide is engineered to bind to the same receptors but resist breakdown, so the signal lasts far longer. One weekly injection maintains that elevated receptor activity across all seven days. You do not feel dramatically "full" in the way you might after a large meal; the effect is subtler, cravings diminish, portions that once felt too small start to feel sufficient, and the background preoccupation with food that many people describe tends to quieten. The NHS medicines page for semaglutide explains this mechanism in patient-friendly terms and is worth reading alongside this page.

Gastric emptying slowing is one reason the common early side effects are gastrointestinal: nausea, loose stools, and sometimes reflux, particularly after starting or after a dose increase. These usually ease within days to a couple of weeks as the body adjusts. Dose titration (beginning at 0.25mg and increasing gradually) exists partly to give the digestive system time to settle.

What the STEP 1 trial actually showed, and what it means in practice

The headline figure from STEP 1 is around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose, versus roughly 2.4% for placebo, in adults with obesity or overweight and at least one weight-related condition. Over two-thirds of participants lost at least 10% of their body weight. Those are population averages; individual results vary, and factors including starting weight, diet, activity and adherence all matter. NICE and the NHS are clear that there are no guarantees, and clinical guidance suggests reviewing whether to continue if weight loss is less than 5% after six months at the highest tolerated dose.

A newer approved dose of 7.2mg (the MHRA approved a dedicated single-dose 7.2mg pen on 14 April 2026) showed around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. The starting dose and titration schedule remain the same regardless of which maintenance dose a prescriber ultimately selects. For a broader picture of the treatment and how it compares with alternatives, the Wegovy overview on our site covers the full context.

Worth knowing: the weight loss seen in trials came alongside structured lifestyle support. Wegovy is not designed to replace dietary changes and increased activity (it makes those changes easier to sustain by reducing appetite) but the two work together.

Which body systems feel the effect, and over what timescale

The effects are not confined to the stomach. GLP-1 receptors are present in the brain, heart, kidneys and liver, which is one reason semaglutide has been studied across a range of conditions. For most people starting Wegovy for weight management, if you want a fuller picture of how Wegovy works in the body, the practical sequence runs roughly like this: nausea and reduced appetite are often noticeable within the first week or two; measurable weight change typically becomes apparent from week four onwards; the more substantial reductions seen in trials accumulate over months, not weeks.

The liver sees indirect benefits as body weight falls, and blood pressure and cholesterol levels often improve alongside weight loss, though Wegovy is not licensed specifically for those purposes in this context. Skin changes, including concerns such as stretch marks during weight loss, are questions our team hears regularly, they reflect the fact that meaningful weight change affects multiple body systems at once.

Appetite hormone balance also shifts. Ghrelin, often called the hunger hormone, tends to rise when someone loses weight through calorie restriction alone, one reason conventional diets are so hard to sustain. If you are interested in what Wegovy does to your body beyond appetite, including these hormonal effects, some evidence suggests GLP-1 agonists moderate this rebound effect, though the research is still developing. The NICE appraisal of semaglutide (TA875) references the clinical evidence base for the treatment's effectiveness as part of a managed weight-loss programme.

Eligibility, safety considerations, and where to go next

Wegovy is a prescription-only medicine licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. It is not licensed for use in pregnancy, during breastfeeding, or when trying to conceive. Anyone under 18 is outside the licensed indication. People with a personal or family history of medullary thyroid carcinoma, or certain inflammatory bowel conditions, should discuss their history with a prescriber before starting.

If you are curious about what treatment might be suitable given your own circumstances, the weight-loss treatment overview on our site sets out the options clearly. Understanding how Wegovy works is a reasonable first step, and often one of the questions our prescribers are most glad to talk through at consultation. If cost is part of your thinking, the Wegovy pricing page explains what a private prescription typically involves and what is included. When you are ready, checking your eligibility takes only a few minutes and is assessed the same day by a GPhC-registered Independent Prescriber, not by software.